Two stocks in Healthcare
Fresenius SE & Co. KGaA vs Genmab A/S: profit, growth, debt and price compared
Genmab A/S is stronger on 3 of 6 figures: profit margin, sales growth and price trend. Fresenius SE & Co. KGaA is stronger on 2: debt and price for its expected profit.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Fresenius SE & Co. KGaAFRE.DE | Genmab A/SGMAB.CO | |
|---|---|---|
| Net margin | 6.6% | Stronger: 17.0% |
| Revenue growth, past year | +5.90% | Stronger: +16.10% |
| Debt to equity | Stronger: 57.0% | 82.1% |
| Forward P/E | Stronger: 13.7× | 29.9× |
| Dividend yield | 1.95% | — |
| Analysts | Strong buy · 14 | Strong buy · 13 |
| From its 200-day average | +19.2% | Stronger: +54.9% |
Share price over the past year
- Fresenius SE & Co. KGaA+14.2%
- Genmab A/S+78.6%
20 Nov 202518 Nov 2026
Fresenius SE & Co. KGaA or Genmab A/S: which is stronger?
- GMAB.CO
Which is more profitable?
Genmab A/S keeps more of each sale as profit: 17.0% against 6.6%.
- GMAB.CO
Which is growing its sales faster?
Genmab A/S is growing its sales faster: +16.10% over the past year, against +5.90%.
- FRE.DE
Which has borrowed less?
Fresenius SE & Co. KGaA has borrowed less: its debt is 57.0% of what its shareholders own, against 82.1% for Genmab A/S.
- FRE.DE
Which costs less for the profit it is expected to make?
Fresenius SE & Co. KGaA costs less for the profit it is expected to make: 13.7× its forward earnings, against 29.9×.
Which do analysts rate higher?
Analysts rate both the same: Strong buy.
- GMAB.CO
Which is in the stronger price trend?
Genmab A/S' price is in the stronger trend: 54.9% above its 200-day average, against 19.2% above.
What each company does
FRE.DEFresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa.
Reports results on 24 February 2027
GMAB.COGenmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Reports results on 16 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.